Google
Trusted Resources: News & Events
Latest announcements and gatherings
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCD
Prolong Pharmaceuticals’ investigational drug for treatment of sickle cell disease (SCD)-associated complications, Sanguinate, showed promising results in patients experiencing vaso-occlusive crisis (VOC).
According to the research study, “SANGUINATE Returns RBCs To More Normal Morphology In Patients With VOC,” presented at the 2017 Annual Symposium of the Foundation for Sickle Cell Disease Research (FSCDR) in Fort Lauderdale, Florida, this new treatment was able to restore the shape of red blood cells, improving the VOC symptoms in SCD patients.
+myBinderRelated Content
-
Foundation for Women and Girls ConferenceJoin Foundation for Women & Girls wi...
-
Johns Hopkins researchers offer new protocol to potentially cure sickle cell diseaseThere's new hope for patients who have b...
-
The Participation of Cohabitants With Sickle Cell Disease in Health Care: A Bibliographic StudyThis paper aims to analyze the published...
-
HABIT Efficacy and Sustainability Trial, a Multi-Center Randomized Controlled Trial to Improve Hydroxyurea Adherence...Background: Hydroxyurea (HU) is recomme...
-
Gene therapies could transform the treatment of sickle cell diseaseManny Johnson keeps catching h...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
How to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.